Communiqués Royalty Pharma plc

Actions

RPRX

GB00BMVP7Y09

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 03/09/2026			Varia. 5j.	Varia. 1 janv.
63,88 ^USD	+1,22%		+3,17%	+65,32%

02/09	Le traitement de Teva contre les troubles immunitaires atteint son objectif principal en phase intermédiaire	RE
13/08	Bourse : Valneva creuse ses pertes, Cerebras coule, Lenovo flambe

Communiqués

12/08	Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million	GL
05/08	Royalty Pharma: Q2 Earnings Snapshot	AQ
05/08	Royalty Pharma reports second quarter 2026 results	GL
03/08	Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives	GL
23/07	Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune	AQ
23/07	Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma	AQ
22/07	Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune	GL
22/07	Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune	AQ
17/07	Royalty Pharma declares third quarter 2026 dividend	GL
15/07	Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026	GL
04/06	Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference	GL
13/05	Royalty Pharma : Q1 2026 Financial Results Call Transcript	PU
07/05	Royalty Pharma to present at upcoming investor conferences	GL
06/05	Royalty Pharma : Q1 2026 Financial Results Presentation	PU
06/05	Royalty Pharma : Q1 2026 Press Release	PU
06/05	Royalty Pharma: Q1 Earnings Snapshot	AQ
06/05	Royalty Pharma reports first quarter 2026 results	GL
21/04	Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation	GL
17/04	Royalty Pharma Declares Second Quarter 2026 Dividend	GL
15/04	Royalty Pharma : Q1 2026 Pre-Quarterly Results Communication	PU
15/04	Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026	GL
14/04	Royalty Pharma : 2025 Corporate Responsibility Report pdf	PU
30/03	Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases	GL
23/03	Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence	GL
17/03	Royalty Pharma Announces Expansion of Leadership Team	GL